First Week of IMNM July 2026 Options Trading

Stock Options Channel highlights option strategies on Immunome Inc (IMNM): the $18 put has a $4.10 bid (implying a $13.90 net purchase basis vs. $18.68 market) and is calculated to have a 72% chance of expiring worthless, yielding 22.78% (35.38% annualized) if so. The $20 call has a $4.50 bid; selling it as a covered call from the $18.68 current price implies a 31.16% total return to July 2026 and a 33% chance of expiring worthless, representing a 24.09% (37.42% annualized) YieldBoost. Implied volatilities are high (put 128%, call 121%) versus trailing 12-month volatility of 76%, underscoring elevated option premia and speculative trade opportunities.

Analysis

Market structure: Elevated option premia create a transfer of expected return from volatility buyers to premium sellers; primary beneficiaries are structured-product sellers, yield-seeking credit funds and tactical long-biotech holders willing to monetize exposure. Increased hedging/speculative flow compresses float liquidity for the equity and raises effective funding cost for the issuer, pressuring small-cap biotech pricing power versus larger peers.

Risk assessment: Tail risks include a negative clinical/regulatory outcome or a dilutive financing that can crater equity >50% in a single event; in the next 0–90 days gamma/IV can swing violently around any headline, while 6–18 months determines path to cash neutrality or re-rating. Hidden dependencies include sector correlation spikes and index rebalances that can amplify moves; primary catalysts are trial readouts, filings, and any 12–18 month financing windows.

Trade implications: Prefer selling premium with defined-risk structures (cash-secured put credit spreads, covered-call overlays, or short-dated iron condors) sized 1–3% of portfolio to capture IV risk premium while limiting tail exposure. Use a dollar‑neutral pair: long IMNM equity/options vs short IBB (or similar biotech ETF) to remove market beta; target realized P/L from IV contraction >25% within 6–12 months.

Contrarian angles: Consensus ignores that IV often mean‑reverts 30–60% post-catalyst, so option sellers can be overcompensated if downside is limited; conversely, premium harvesting is underdone when issuer liquidity is unclear — selling naked premium without hard stop is a fragile trade. Historical parallels show rapid unwind when capital markets tighten, producing asymmetric losses for sellers who aren’t cash-secured.

Key Decisions for Investors

• Establish a tactical 1–2% long exposure to IMNM equity and simultaneously sell a cash‑secured put spread (9–12 month expiry, 10–15% OTM sell leg, 10–15% width) sized so max loss = 1–2% of portfolio; close or roll if IV compresses >30% or if company discloses a financing need within 120 days.
• Buy a modest long position (1–2%) and write a 12–18 month covered-call ~10–20% OTM to target a total return >25% annualized; buy back/roll if underlying rallies >30% or if the covered‑call premium decays <40% of initial value within 60 days.
• Deploy defined‑risk put credit spreads instead of naked puts: sell 9–12 month put and buy a lower strike to cap downside, use trade sizing of 2–3% notional, and limit capital at risk per trade to 1.5% of portfolio. Exit if IV narrows by >35% or if downside breach of >35% from entry occurs.
• Implement a relative value trade: go long IMNM (equity or LEAP call) and short IBB (ETF) using dollar neutrality (e.g., 1:0.8) to isolate idiosyncratic upside; rebalance monthly and unwind when IMNM outperforms the ETF by 20% or upon any sector-wide de‑risking event.
• Do not sell naked premium uncovered. Monitor three triggers before increasing size: 1) cash runway >12 months post any disclosed financing; 2) next clinical/regulatory catalyst date within 30–180 days; 3) IV/realized vol gap narrowing to <1.2x — only then consider scaling positions beyond initial sizing.